184 related articles for article (PubMed ID: 30519791)
21. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.
Adamczuk K; Schaeverbeke J; Nelissen N; Neyens V; Vandenbulcke M; Goffin K; Lilja J; Hilven K; Dupont P; Van Laere K; Vandenberghe R
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):142-151. PubMed ID: 26260650
[TBL] [Abstract][Full Text] [Related]
22. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
23. rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data.
Iaccarino L; La Joie R; Koeppe R; Siegel BA; Hillner BE; Gatsonis C; Whitmer RA; Carrillo MC; Apgar C; Camacho MR; Nosheny R; Rabinovici GD;
Neuroimage; 2022 Feb; 246():118775. PubMed ID: 34890793
[TBL] [Abstract][Full Text] [Related]
24. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale.
Navitsky M; Joshi AD; Kennedy I; Klunk WE; Rowe CC; Wong DF; Pontecorvo MJ; Mintun MA; Devous MD
Alzheimers Dement; 2018 Dec; 14(12):1565-1571. PubMed ID: 30006100
[TBL] [Abstract][Full Text] [Related]
25. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.
Royse SK; Minhas DS; Lopresti BJ; Murphy A; Ward T; Koeppe RA; Bullich S; DeSanti S; Jagust WJ; Landau SM;
Alzheimers Res Ther; 2021 May; 13(1):99. PubMed ID: 33971965
[TBL] [Abstract][Full Text] [Related]
26. Software compatibility analysis for quantitative measures of [
Pemberton HG; Buckley C; Battle M; Bollack A; Patel V; Tomova P; Cooke D; Balhorn W; Hegedorn K; Lilja J; Brand C; Farrar G
EJNMMI Res; 2023 May; 13(1):48. PubMed ID: 37225974
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Standardized Uptake Value Ratio Calculations in Amyloid Positron Emission Tomography Brain Imaging.
Knešaurek K; Warnock G; Kostakoglu L; Burger C;
World J Nucl Med; 2018; 17(1):21-26. PubMed ID: 29398961
[TBL] [Abstract][Full Text] [Related]
28. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.
Salvadó G; Molinuevo JL; Brugulat-Serrat A; Falcon C; Grau-Rivera O; Suárez-Calvet M; Pavia J; Niñerola-Baizán A; Perissinotti A; Lomeña F; Minguillon C; Fauria K; Zetterberg H; Blennow K; Gispert JD;
Alzheimers Res Ther; 2019 Mar; 11(1):27. PubMed ID: 30902090
[TBL] [Abstract][Full Text] [Related]
29. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
Vandenberghe R; Van Laere K; Ivanoiu A; Salmon E; Bastin C; Triau E; Hasselbalch S; Law I; Andersen A; Korner A; Minthon L; Garraux G; Nelissen N; Bormans G; Buckley C; Owenius R; Thurfjell L; Farrar G; Brooks DJ
Ann Neurol; 2010 Sep; 68(3):319-29. PubMed ID: 20687209
[TBL] [Abstract][Full Text] [Related]
30. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging.
Akamatsu G; Ikari Y; Nishio T; Nishida H; Ohnishi A; Aita K; Sasaki M; Sasaki M; Senda M
Ann Nucl Med; 2016 Jan; 30(1):18-28. PubMed ID: 26337533
[TBL] [Abstract][Full Text] [Related]
31. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI.
Akamatsu G; Ikari Y; Ohnishi A; Nishida H; Aita K; Sasaki M; Yamamoto Y; Sasaki M; Senda M
Phys Med Biol; 2016 Aug; 61(15):5768-80. PubMed ID: 27405579
[TBL] [Abstract][Full Text] [Related]
32. Harmonizing florbetapir and PiB PET measurements of cortical Aβ plaque burden using multiple regions-of-interest and machine learning techniques: An alternative to the Centiloid approach.
Chen K; Ghisays V; Luo J; Chen Y; Lee W; Wu T; Reiman EM; Su Y
Alzheimers Dement; 2024 Mar; 20(3):2165-2172. PubMed ID: 38276892
[TBL] [Abstract][Full Text] [Related]
33. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
[TBL] [Abstract][Full Text] [Related]
34. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.
Miki T; Shimada H; Kim JS; Yamamoto Y; Sugino M; Kowa H; Heurling K; Zanette M; Sherwin PF; Senda M
Ann Nucl Med; 2017 Apr; 31(3):260-272. PubMed ID: 28181118
[TBL] [Abstract][Full Text] [Related]
35. Identifying Mild Alzheimer's Disease With First 30-Min
Shen C; Wang Z; Chen H; Bai Y; Li X; Liang D; Liu X; Zheng H; Wang M; Yang Y; Wang H; Sun T
Front Aging Neurosci; 2022; 14():785495. PubMed ID: 35450057
[TBL] [Abstract][Full Text] [Related]
36. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.
Jovalekic A; Roé-Vellvé N; Koglin N; Quintana ML; Nelson A; Diemling M; Lilja J; Gómez-González JP; Doré V; Bourgeat P; Whittington A; Gunn R; Stephens AW; Bullich S
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3276-3289. PubMed ID: 37300571
[TBL] [Abstract][Full Text] [Related]
37. Feasibility evaluation of middle-phase
Wu CH; Lu YH; Lee TH; Tu CY; Fuh JL; Wang YF; Yang BH
Quant Imaging Med Surg; 2023 Aug; 13(8):4806-4815. PubMed ID: 37581034
[TBL] [Abstract][Full Text] [Related]
38. Comparison of MR-less PiB SUVR quantification methods.
Bourgeat P; Villemagne VL; Dore V; Brown B; Macaulay SL; Martins R; Masters CL; Ames D; Ellis K; Rowe CC; Salvado O; Fripp J;
Neurobiol Aging; 2015 Jan; 36 Suppl 1():S159-66. PubMed ID: 25257985
[TBL] [Abstract][Full Text] [Related]
39. Development and evaluation of an automated quantification tool for amyloid PET images.
Tsubaki Y; Akamatsu G; Shimokawa N; Katsube S; Takashima A; Sasaki M;
EJNMMI Phys; 2020 Sep; 7(1):59. PubMed ID: 32990884
[TBL] [Abstract][Full Text] [Related]
40. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
